AI-ACCELERATED DRUG DISCOVERY
Launching AI-driven libraries targeting 8,801 proteins
TORONTO, ON, October 24, 2024 – In a strategic collaboration, Reaxense Inc., a leading provider of chemical synthesis services, and Receptor.AI, a pioneer in AI-driven drug discovery, are launching a comprehensive line of focused on-demand libraries targeting 8,801 proteins. Leveraging cutting-edge virtual screening and advanced parameter assessment, these libraries represent the future of precision drug discovery.
Powered by Receptor.AI's AI-powered multi-platform ecosystem, the library design integrates its various components—from protein structural analysis to the multitask model for ADMET prediction. This collaboration delivers superior compounds by outperforming traditional drug discovery methods, producing molecules with heightened activity, selectivity, and safety.
"We are excited to bring together Reaxense’s expertise in custom synthesis with Receptor.AI’s advanced AI capabilities," said Dr. Yaroslav Bilokin, Associate Director at Reaxense Inc. "This partnership offers comprehensive solutions to the pharmaceutical and biotechnology sectors, accelerating the discovery of new therapeutics."
The compounds are meticulously selected from a 60 billion virtual and stock chemical space and generated using direct in-pocket AI molecular generation. Once identified, Reaxense ensures rapid synthesis and delivery, enabling seamless integration into research pipelines.
Each library features a broad range of potent modulators, supported by 38 ADME-Tox parameters and 32 physicochemical and drug-likeness parameters. Furthermore, all compounds are provided with docking poses, affinity scores, and activity profiles, offering comprehensive insights into their potential.
"Our AI-driven approach to drug discovery significantly enhances precision in identifying effective therapeutic candidates," stated Alan Nafiiev, CEO of Receptor.AI. "By collaborating with Reaxense, we’re able to transition these innovative solutions from virtual to physical compounds more efficiently than ever before."
This partnership strengthens the companies’ mutual commitment to accelerating the development of cutting-edge therapeutic solutions, particularly for hard-to-target proteins and enzymes, by utilizing advanced AI and molecular modeling processes.
About Receptor.AI
Founded in 2021, Receptor.AI specializes in AI-accelerated drug discovery with a focus on precision medicine. Through its proprietary AI-powered multi-platform ecosystem, Receptor.AI supports the entire drug discovery pipeline, including target identification, drug candidate design, and optimization. The company has formed strategic partnerships across the biotech sector, achieving an 86% success rate in its projects.
About Reaxense Inc.
Established in 2011, Reaxense Inc. is an Ontario-based chemical and biotechnology company specializing in custom synthesis and drug-like molecule production. The company offers a wide range of high-throughput screening, fragment, and focused libraries, providing tailored solutions for pharmaceutical, academic, and government sectors.
For Media Enquiries
tetiana.skakun@receptor.ai
